ANIK

Over the past six months, Anika Therapeutics' stock price has seen a significant increase of 52.27%. Q4 and Full Year 2025 financial results reported flat revenue year-over-year but with gross margin expansion, leading to a stock gain. Q1 2026 financial results showed a year-over-year revenue increase, exceeding analyst expectations, driven by strength in both OEM and Commercial channels. The company is progressing with regulatory milestones for its pipeline products, including FDA responses for Hyalofast and Cingal. The upcoming transition in leadership to current CFO and COO, Stephen Griffin, is expected to bring continued operational improvements.